Diaceutics Regulatory News (DXRX)

Diaceutics PLC

("Diaceutics" or the "Company")

Investor presentation

Diaceutics PLC (AIM: DXRX), the data analytics and implementation services company which services the global pharmaceutical industry, announces it will hold an investor presentation on Monday, 17 June 2019.

The investor event will take place at the Copper Bar, Balls Brothers, 6 Adams Court, London EC2N 1DX at 4.30pm for a 4.45pm start. This will be followed by drinks and canapés, and a chance to network with the management.

Peter Keeling, CEO, will provide an introduction to the Company and an overview of the business.

If you would like to register to attend the investor briefing or require further information, please contact Walbrook PR on 020 7933 8780 or email diaceutics@walbrookpr.com.

No new material information will be disclosed at the event.

Enquiries:

About Diaceutics

Diaceutics has established a suite of data-driven products and implementation services powered by the data held in its proprietary database. Its products and services are focused on optimising its clients' strategies for the development and launch of precision medicines and specifically, the diagnostic testing required to guide selection of such medicines. The Company provides services to 20 of the 30 largest global pharmaceutical companies.

Since its inception in 2005, Diaceutics has focused on the diagnostic testing market, collating large amounts of laboratory, patient (on an anonymised and aggregated basis), claims and payor data which it uses to deliver diagnostic testing strategies to its clients. The Group has amassed a set of more than 115 million patient records from over 2,500 laboratories across 35 countries around the world. As part of this data collection, it has accumulated a proprietary database of laboratory capabilities across the industry.

About Precision Medicines

Precision medicines (or therapies) are a class of drug tailored to individual patient groups dependent on molecular or genetic factors of the individual. Today, they are used for treatment in oncology as well as other disease areas such as multiple sclerosis and rheumatoid arthritis. The increasing use of precision medicines results from the fact that some drugs have demonstrated significant positive clinical results in some patients but have been shown to be less effective or less safe across the entire patient population.

Given the specific nature of precision therapeutics, the successful roll-out of these medicines by a pharmaceutical company is increasingly reliant on having effective and wide-spread testing available for doctors and patients from launch.

Diaceutics' products and services

Diaceutics' products and services are predominantly focused on diagnostic tests carried out in laboratories which are used alongside a precision medicine to identify which patients will benefit most from that drug. From the pharmaceutical company's perspective, it is essential that from launch, it has optimised the practical process for testing of potential patients by labs to ensure the highest levels of drug sales from the outset. Failure to have effective testing can significantly reduce the adoption of the relevant drug. Despite the increasing importance of effective diagnostic testing, the testing market itself remains highly fragmented and the pharmaceutical industry has varied insight into it. The Directors believe that the addressable market for their specific services today is approximately US$0.5 billion. With expected market growth in the number of test dependent therapies alongside increased investment by pharma to remove testing hurdles to seamless treatment, Diaceutics forecast the overall market will increase to US$2.5 billion by 2023.

The Group's services are split into the following four discrete, sequential modules:

· Landscape - initial views on the testing environment for pharmaceutical companies that often have little insight into the actual data required to make decisions in advance of a launch.

· Planning - advising on steps to ensure rapid and effective test adoption, including advice on how tests should be developed, who they should be developed with and how should they be optimally communicated to physicians and patients.

· Implementation - identifying and solving issues with leading laboratories relating to the adoption and efficacy of testing.

· Tracking - ongoing post launch analysis to understand how testing is promoting or restricting access to precision therapy.

The Directors believe that these services benefit pharma clients with improved return on investment, reduced time to peak market penetration and greater revenue potential in relation to their precision therapeutic development programmes. The Group's products also improve testing outcomes for patients, enabling better access to the right drug at the right time. During 2018, the Group, which is headquartered in Belfast, Northern Ireland and has offices in Dundalk, Co. Louth, New Jersey in the US and in Singapore, had an average of 65 full time employees in 17 different countries. The Group achieved compound annual revenue growth in sales of over 50 per cent from 2016 to 2018.